secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K/A
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001628280-23-037882
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports Q3 FYARRO sales $6M (+40% YoY); net loss $16.3M; PRECISION1 interim on track for Dec 2023
--------------------------------------------------------------------------------

- FYARRO sales $6.0M in Q3 2023, up 40% YoY from $4.2M; net loss $16.3M vs $14.5M.
- Cash, equivalents & investments $119.3M as of Sep 30, 2023, expected to fund operations into 2025.
- PRECISION1 interim analysis on first third of patients (n=40) on track for mid-December 2023.
- Dave Lennon appointed President and CEO in early October 2023.
- Phase 2 trials initiated for endometrial cancer (nab-sirolimus + letrozole) and neuroendocrine tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/0001628280-23-037882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023037882/aadi-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer